

# LAP2 siRNA (h): sc-43386

## BACKGROUND

The nuclear envelope separates the nucleoplasm from the cytoplasm in eukaryotic cells and includes the outer and inner nuclear membrane, nuclear pore complexes and the nuclear lamina. The nuclear lamina contains intermediate filament-type proteins called lamins that form a dense network to strengthen and stabilize the nuclear envelope. Lamina-associated polypeptide 2 (LAP2) is also known as thymopoietin. LAP2 is a nuclear envelope protein and contains an amino-terminal region called the LAP2-emerin-MAN1 or LEM motif. LAP2 also contains a unique DNA-binding amino-terminal domain. Alternative splicing produces six isoforms ( $\alpha$ - $\gamma$ ) of mammalian LAP2 and three isoforms in *Xenopus* LAP2. LAP2 $\alpha$  and LAP2 $\beta$  associate with chromosomal barrier-to-autointegration factor (BAF) and may play a role in stabilizing chromatin structure. LAP2 $\beta$  also binds to lamin B. LAP2 $\alpha$  is a non-membrane isoform of LAP2 that associates with the internal nucleoskeleton and binds lamin A. The gene encoding human LAP2 maps to chromosome 12q23.1.

## REFERENCES

- Harris, C.A., et al. 1995. Structure and mapping of the human thymopoietin (TMPO) gene and relationship of human TMPO  $\beta$  to rat lamin-associated polypeptide 2. *Genomics* 28: 198-205.
- Lin, F., et al. 2000. MAN1, an inner nuclear membrane protein that shares the LEM domain with lamina-associated polypeptide 2 and emerlin. *J. Biol. Chem.* 275: 4840-4847.
- Dechat, T., et al. 2000. Review: lamina-associated polypeptide 2 isoforms and related proteins in cell cycle-dependent nuclear structure dynamics. *J. Struct. Biol.* 129: 335-345.
- Dechat, T., et al. 2000. Lamina-associated polypeptide 2 $\alpha$  binds intranuclear A-type lamins. *J. Cell Sci.* 113: 3473-3484.
- Cai, M., et al. 2001. Solution structure of the constant region of nuclear envelope protein LAP2 reveals two LEM-domain structures: one binds BAF and the other binds DNA. *EMBO J.* 20: 4399-4407.

## CHROMOSOMAL LOCATION

Genetic locus: TMPO (human) mapping to 12q23.1.

## PRODUCT

LAP2 siRNA (h) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10  $\mu$ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see LAP2 shRNA Plasmid (h): sc-43386-SH and LAP2 shRNA (h) Lentiviral Particles: sc-43386-V as alternate gene silencing products.

For independent verification of LAP2 (h) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-43386A, sc-43386B and sc-43386C.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) for detailed protocols and support products.

## STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330  $\mu$ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330  $\mu$ l of RNase-free water makes a 10  $\mu$ M solution in a 10  $\mu$ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

## APPLICATIONS

LAP2 siRNA (h) is recommended for the inhibition of LAP2 expression in human cells.

## SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10  $\mu$ M in 66  $\mu$ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

## GENE EXPRESSION MONITORING

LAP2 (3A3): sc-81610 is recommended as a control antibody for monitoring of LAP2 gene expression knockdown by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) or immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgG $\kappa$  BP-HRP: sc-516102 or m-IgG $\kappa$  BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker<sup>™</sup> Molecular Weight Standards: sc-2035, UltraCruz<sup>®</sup> Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgG $\kappa$  BP-FITC: sc-516140 or m-IgG $\kappa$  BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz<sup>®</sup> Mounting Medium: sc-24941 or UltraCruz<sup>®</sup> Hard-set Mounting Medium: sc-359850.

## RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor LAP2 gene expression knockdown using RT-PCR Primer: LAP2 (h)-PR: sc-43386-PR (20  $\mu$ l, 524 bp). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

## SELECT PRODUCT CITATIONS

- Ward, M.C., et al. 2011. Deregulated LAP2 $\alpha$  expression in cervical cancer associates with aberrant E2F and p53 activities. *IJMB Life* 63: 1018-1026.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.